Advances in Targeted Therapy of Neuroblastoma
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 126
Special Issue Editor
2. Research Center for Cancer Biology, China Medical University, Taichung 110122, Taiwan
3. Institute of Biochemistry and Molecular Biology, College of Life Sciences, China Medical University, Taichung 110122, Taiwan
Interests: cancer targeted therapy; cancer immunotherapy; post-translational modifications; chromatin remodeling
Special Issue Information
Dear Colleagues,
Neuroblastoma is the most common extracranial solid tumor of childhood. Over the past few decades, the advances in targeted therapy of neuroblastoma have greatly improved patient survival outcomes, such as ALK inhibitors, RAS-MAPK inhibitors, targeting MYCN through AURORA and BET inhibitors, epigenetic therapies, and GD2-based immunotherapy. However, many patients still develop relapsed and refractory disease. Recent progress in the developmental origin and phenotypic plasticity of neuroblastoma has provided new insights into the pathogenesis of neuroblastoma. This knowledge, along with the cutting-edge single-cell applications of next-generation sequencing technologies, will inform a further delineation of the molecular basis of neuroblastoma, as well as the development of novel biomarkers and therapies for precision medicine strategies.
Dr. Xing-Guo Li
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neuroblastoma
- targeted therapy
- single-cell NGS technologies
- epigenetic therapy
- immunotherapy
